Evaluation of the STAT3 inhibitor GLG‑302 for the prevention of estrogen receptor‑positive and ‑negative mammary cancers
Robert H. Shoemaker(Frederick National Laboratory for Cancer Research), Clinton J. Grubbs(University of Alabama at Birmingham)
Cited by 6
Related Papers
Targeting Glutamine Metabolism to Enhance Immunoprevention of EGFR‐Driven Lung Cancer
|Advanced Science|2022|71
Potentiation of Kras peptide cancer vaccine by avasimibe, a cholesterol modulator
|EBioMedicine|2019|59